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Abstract 
Pneumonitis is a rare but serious complication associated with paclitaxel and/or 
trastuzumab treatment. We report a 51-year-old female patient with locally advanced 
breast cancer who presented with shortness of breath, fever, dry cough and pulmonary 
infiltrates. She had been treated without complications for 10 weeks with paclitaxel 
(Taxol) and trastuzumab (Herceptin) as neoadjuvant therapy, with complete clinical 
and pathological response. Infections and cardiomyopathy were excluded as causes of 
her symptoms. Bronchoscopy and biopsy were performed and a diagnosis of drug-
induced interstitial pneumonitis was made. After treatment with steroids, the patient 
showed a significant response in less than 24 h; she was discharged home without the 
need for oxygen less than 48 h after therapy initiation. Although no causative association 
could be found between either trastuzumab or paclitaxel and this patient’s pulmonary 
syndrome, the potential for such toxicity should be considered, especially as 
paclitaxel/trastuzumab is a vey common combination therapy for breast cancer. 
 
Introduction 
Paclitaxel and trastuzumab combination therapy is a well-known treatment for breast 
cancer [1]. Major adverse effects include peripheral neuropathy, myelotoxicity, 
bradycardia, hypotension, arthralgia, myalgia, granulocytopenia and hypersensitivity [2, 
3]. To date, several cases of patients developing paclitaxel-induced interstitial 
pneumonitis have been reported, with estimated frequencies of 0.73–12% [4]. 
Trastuzumab-induced pneumonitis may present as rapidly progressive pulmonary 
infiltrate respiratory failure after the administration of 1 dose of trastuzumab or after 6 
weeks of therapy. The incidence of trastuzumab-induced pneumonitis is 0.4–0.6% [4].  
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Although there is one report of fatal pneumonitis associated with docetaxel 
(Taxotere)/trastuzumab therapy, no fatalities associated with paclitaxel/trastuzumab 
combination therapy have been reported to date. However, awareness of the potential for 
such fatal toxicity is important. 
Case Report 
A 51-year-old female patient, nonsmoker and with no comorbid disease, was diagnosed with locally 
advanced left breast cancer (T2N1M0). HER2/neu was overexpressed in the primary tumor. Estrogen 
and progesterone receptors were negative. Neoadjuvant treatment comprised paclitaxel 80 mg/m
2 
weekly for 12 weeks concurrent with trastuzumab 4 mg/m
2 loading dose in week 1, then 2 mg/m
2 weekly 
for 11 weeks. As per protocol, the patient was given dexamethasone prior to chemotherapy. The patient 
had completed 9 doses of both therapies with no complications. When she was due for week 10 of the 
therapy, she complained of shortness of breath, dry cough and fever. Her clinical examination revealed 
the following: temperature 39.6°C, heart rate 104 bpm, BP 96/33 mm Hg, respiratory rate 30 cycles/min 
and SpO2 84% on room air. 
Chest examination showed bilateral diffuse crepitation and wheezing. The patient was admitted to 
hospital and started on therapy with 4 liters O2 per nasal canula, and Tazocin (piperacillin sodium- 
tazobactam sodium) 4.5 g every 8 h and vancomycin 1 g every 12 h empirically after drawing blood for 
culture and sensitivity. At this time, the patient was not neutropenic and the following laboratory values 
were noted: WBC 5.5 × 10
9/l, ANC 4.3 × 10
9/l, Hb 91 g/l and platelets 315 × 10
9/l. Her renal and liver 
functions were within normal range, echocardiography was normal, both blood and sputum cultures 
were negative for acid-fast bacteria and fungal infection, and urine culture showed no growth. X-ray 
showed ground-glass opacification of the lungs (fig. 1) and spiral chest CT showed satisfactory 
opacification of the pulmonary trunk, and right and left main pulmonary arteries, with no evidence of 
central pulmonary embolism. Bilateral airspace disease consistent with pulmonary edema was noted, 
along with no detectable lung nodules, and no evidence of either pleural or pericardial effusion (fig. 2a, 
b, c). Special stains for AFB, fungus, Pneumonitis jirovecii (carinii) pneumonia and CMV 
immunohistochemistry were all negative. 
Bronchoscopic lung biopsy showed moderate interstitial inflammatory infiltrate composed of 
polymorphonuclear leukocytes, lymphocytes and some histiocytes forming occasional aggregates. The 
alveolar spaces showed focal deposits of fibrin; there was focal pneumocyte atypia and hyperplasia, as 
well as focal intra-alveolar hemorrhage. Bronchoalveolar lavage was negative for malignant cells and 
viral inclusion bodies; however, reactive lymphocytes were present. Gram stain culture findings were 
negative. Scattered pulmonary macrophages were noted against a background of reactive lymphocytes, 
and only occasional eosinophils were seen. Based on the above-mentioned findings, a diagnosis of acute 
interstitial pneumonitis was made. Although the patient’s fever had subsided and her blood pressure 
had begun to normalize, lung auscultation revealed the same initial crepitations and the patient was still 
in need of O2 supply (4 l/h). 
A pulmonary function test (spirometry) yielded the following prebronchodilator results: FEV1 
49.9% and FVC 43.5%; the postbronchodilator differences were 16% for FEV1 and 27.6% for FVC. Due 
to a very short exhalation time of 1–2 s max., the patient was unable to exhale maximally in order to 
record total lung capacity Furthermore, the patient refused to complete the postbronchodilator 
spirometry test due to shortness of breath. Given the data at hand, the best possible flow volume loop 
was chosen. 
As there was no indication of any type of infection, the case was diagnosed as drug-induced 
interstitial pneumonitis, antibiotics were withdrawn and treatment with prednisone 40 mg orally once 
daily was begun within 18 h of initial presentation. 
The patient’s crepitations disappeared and her oxygen saturation reached 95% on room air. A chest 
X-ray taken 18 h after initiation of prednisone (fig. 3a) showed improvement in the lung picture 
compared to the initial radiograph. A follow-up X-ray taken 48 h after initiation of prednisone (fig. 3b) 
was completely normal, so the patient was discharged home in very good general condition without the 
need for O2 supply. Follow-up continued in the outpatient clinic, including the completion of a 10-day 
course of prednisone.  
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Discussion 
Drug-induced infiltrative lung disease (DI-ILD) is the most common form of anti-
neoplastic agent-induced respiratory disease. Patterns of DI-ILD are non-specific 
interstitial pneumonia, eosinophilic pneumonia, hypersensitivity pneumonitis, 
pulmonary fibrosis, or organizing pneumonia [5]. Early withdrawal of the causative drug 
will often lead to improvement or even cure of the ILD. Corticosteroids may suppress the 
inflammatory reaction [6, 7]. 
In several series, trastuzumab has been well tolerated, and its addition to chemotherapy 
does not significantly increase the frequency of side effects [8]. Infusion-related events are 
common but rarely severe, and more common during the first administration of the drug 
[9]. In an analysis of the safety of trastuzumab administered to 25,000 patients, the only 
respiratory-associated serious adverse event was bronchospasm [10]. This reaction 
usually occurred within 2.5 h of administration. 
However, apart from the previously described infusion-related bronchospasms, rare 
cases of interstitial pneumonitis have been reported. One patient with organizing 
pneumonia and another with pneumonitis were reported; both events were probably due 
to trastuzumab administration [11, 12]. In trial B-31, four patients in the trastuzumab 
group had interstitial pneumonitis, one of whom died [13]. In the N9831 trial, five 
patients in the trastuzumab group had grade 3+ pneumonitis or pulmonary infiltrates, 
one of whom died [13]. 
Paclitaxel
 acts against tumors through both promotion of microtubule assembly
 and 
inhibition of microtubule disassembly, activities that result
 in disruption of cell division 
and cell death [14]. Hypersensitivity reactions are well-recognized complications
 of 
paclitaxel therapy and typically occur with the first or
 second dose [15]. These reactions 
are characterized by dyspnea,
 hypotension, bronchospasm, urticaria, and erythematous 
rashes.
 Respiratory symptoms may develop hours to weeks after paclitaxel
 administration. 
Severity of these symptoms ranges from mild
 dyspnea to respiratory failure requiring 
mechanical ventilation [15, 16]. The
 mechanism of paclitaxel-induced hypersensitivity 
reactions remains unclear.
 It may be mediated by the release of histamines or other 
vasoactive substances
 similar to anaphylactoid reactions encountered with IV contrast 
agents
 [15], or it may result from a delayed hypersensitivity response [17]. 
Kuip and Muller [18] reported a case in which a patient presented with fever and 
dyspnea after a second dose of docetaxel/trastuzumab. The patient died due to respiratory 
failure 3 weeks later and interstitial pneumonitis was diagnosed at autopsy. In spite of 
accompanying dexamethasone and antihistamines given concurrently with 
paclitaxel/trastuzumab, our patient, like that of Kuip and Muller [18], developed 
interstitial pneumonitis with concomitant complaint of dry cough, fever and dyspnea 
after 9 weeks of therapy. Our patient’s symptoms appeared later than what has been 
reported in the literature for each medication separately. Fortunately, the diagnosis of 
interstitial pneumonitis was expected and confirmed and our patient recovered 
completely. 
This case raises another question: which drug is responsible for this lung complication? 
Paclitaxel or trastuzumab? Or both? Since they have synergistic efficacy against the 
tumor, could they be synergistic in the side effects as well? As the two drugs were given 
concurrently and the patient had no known risk factors to anticipate this reaction, and  
Case Rep Oncol 2011;4:186–191 
DOI: 10.1159/000326063 
Published online: 
April 2, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
189
there is no clear diagnostic test to confirm which drug caused the pneumonitis, it is 
difficult to be sure of the offensive drug. It is well known that trastuzumab infusion-
related events are common but rarely severe, and that they are more common during the 
first administration [19], usually within 2.5 h. Trastuzumab-associated pneumonitis may 
develop many months after initiation of treatment and may run a more insidious course. 
In view of the extensive use of trastuzumab nowadays, trastuzumab-induced 
pneumonitis, if existent, seems rarer than paclitaxel-induced pneumonitis. This leads us 
to conclude that the pneumonitis in our patient was most likely due to paclitaxel. 
Conclusion 
Although pneumonitis is a rare side effect of paclitaxel/trastuzumab administration, it 
is important to be aware of this specific toxicity. Importantly, early recognition and 
appropriate therapy may be life saving. 
 
 
 
 
 
 
Fig. 1. Chest X-ray during acute disease. 
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Fig. 2. Chest CT during acute disease. 
 
 
 
Fig. 3. Chest X-ray 18 h (a) and 48 h (b) after start of prednisone treatment. 
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